Quinazoline derivatives

Patent metadata

Field	Value
Publication number	US-9273013-B2
Application number	US-201313744878-A
Country	US
Kind code	B2
Filing date	Jan 18, 2013
Priority date	May 27, 2003
Publication date	Mar 1, 2016
Grant date	Mar 1, 2016

Abstract

The present invention concerns the compounds of formula

wherein
Z represents NH; Y represents —C 3-9 alkyl-, —C 2-9 alkenyl-, —C 3-7 alkyl-CO—NH optionally substituted with amino, mono- or di(C 1-4 alkyl)amino or C 1-4 alkyloxycarbonylamino-, —C 3-7 alkenyl-CO—NH— optionally substituted with amino, mono- or di(C 1-4 alkyl)amino- or C 1-4 alkyloxycarbonylamino-, C 1-5 alkyl-NR 13 —C 1-5 alkyl-, —C 1-5 alkyl-NR 14 —CO—C 1-5 alkyl-, —C 1-6 alkyl-CO—NH—, —C 1-5 alkyl-CO NR 15 —C 1-5 alkyl-, —C 1-3 alkyl-NH—CO-Het 20 -, —C 1-2 alkyl-CO-Het 21 -CO—, —C 1-2 alkyl-NH—CO—CR 16 R 17 —NH—, —C 1-2 alkyl-CO—NH—CR 18 R 19 —CO—, —C 1-2 alkyl-CO—NR 20 —C 1-3 alkyl-CO—, or —NR 22 —CO—C 1-3 alkyl-NH—; X 1 represents a direct bond, O or —O—C 1-2 alkyl-; X 2 represents a direct bond, —CO—C 1-2 alkyl-, NR 12 , —NR 12 —C 1-2 alkyl, —O—N═CH— or —C 1-2 alkyl-; R 1 and R 2 are hydrogen or halo; R 3 are hydrogen; R 4 represents hydrogen or C 1-4 alkyloxy; R 12 and R 13 are hydrogen or C 1-4 alkyl; R 14 and R 15 are hydrogen; R 16 and R 17 each independently represent hydrogen or C 1-4 alkyl; R 18 and R 19 are hydrogen or C 1-4 alkyl optionally substituted with phenyl or hydroxy; R 20 and R 21 are hydrogen or C 1-4 alkyl optionally substituted with C 1-4 alkyloxy; Het 20 , Het 21 and Het 22 are a heterocycle selected from the group consisting pyrrolidinyl, 2-pyrrolidinonyl or piperidinyl optionally substituted with hydroxy.

First claim

The invention claimed is:

1. An intermediate of formula (XXXIII)

the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein
m represents 1, 2, 3 or 4;
X 2 represents a direct bond, O, —O—C 1-2 alkyl-, CO, —CO—C 1-2 alkyl-, NR 12 , —NR 12 —C 1-2 alkyl-, —CH 2 —, —O—N═CH— or C 1-2 alkyl;
Y 3 represents a C 1-5 alkyl, CO—C 1-5 alkyl or CO—CR 16 R 17 —NH— or C 1-5 alkyl-CO— optionally substituted with amino, mono- or di(C 1-4 alkyl)amino or C 1-4 alkyloxycarbonylamino;
R 1 represents hydrogen, cyano, halo, hydroxy, formyl, C 1-6 alkoxy-, C 1-6 alkyl-, halo-phenyl-carbonylamino-,
C 1-6 alkoxy- substituted with halo,
C 1-4 alkyl substituted with one or where possible two or more substituents selected from hydroxy or halo;

R 2 represents hydrogen, cyano, halo, hydroxy, hydroxycarbonyl-, Het 16 -carbonyl-, C 1-4 alkyloxycarbonyl-, C 1-4 alkylcarbonyl-, aminocarbonyl-, mono- or di(C 1-4 alkyl)aminocarbonyl-, Het 1 , formyl, C 1-4 alkyl, C 2-6 alkynyl-, C 3-6 cycloalkyl-, C 3-6 cycloalkyloxy-, C 1-6 alkoxy-, Ar 5 , Ar 1 -oxy-, dihydroxyborane,
C 1-6 alkoxy- substituted with halo,
C 1-4 alkyl substituted with one or where possible two or more substituents selected from halo, hydroxy or NR 5 R 6 ,
C 1-4 alkylcarbonyl- wherein said C 1-4 alkyl is optionally substituted with one or where possible two or more substituents selected from hydroxy or C 1-4 alkyl-oxy-;

R 3 represents hydrogen, C 1-4 alkyl, or C 1-4 alkyl substituted with one or more substituents selected from halo, C 1-4 alkyloxy-, amino-, mono- or di(C 1-4 alkyl)amino-, C 1-4 alkyl-sulfonyl- or phenyl;
R 5 and R 6 are each independently selected from hydrogen or C 1-4 alkyl;
R 7 and R 8 are each independently selected from hydrogen, C 1-4 alkyl, Het 8 , aminosulfonyl-, mono- or di (C 1-4 alkyl)-aminosulfonyl, hydroxy-C 1-4 alkyl-,
C 1-4 alkyl oxy C 1-4 alkyl , hydroxycarbonyl-C 1-4 alkyl-, C 3-6 cycloalkyl,
Het 9 -carbonyl-C 1-4 alkyl-, Het 10 -carbonyl-, polyhydroxy-C 1-4 alkyl-, Het 11 -C 1-4 alkyl- or
Ar 2 -C 1-4 alkyl-;

R 9 and R 10 are each independently selected from hydrogen, C 1-4 alkyl, C 3-6 cycloalkyl, Het 4 , hydroxy-C 1-4 alkyl-, C 1-4 alkyloxyC 1-4 alkyl- or polyhydroxy-C 1-4 alkyl-;
R 12 represents hydrogen, C 1-4 alkyl, C 1-4 alkyl-oxy-carbonyl-, Het 18 -C 1-4 alkyl-, phenyl-C 1-4 alkyl-oxy-carbonyl-Het 17 , C 2-4 alkenylcarbonyl- optionally substituted with Het 19 -C 1-4 alkylaminocarbonyl-, C 2-4 alkenylsulfonyl-, C 1-4 alkyloxyC 1-4 alkyl- or phenyl optionally substituted with one or where possible two or more substituents selected from hydrogen, hydroxy, amino or C 1-4 alkyloxy-;
R 16 and R 17 each independently represents hydrogen or C 1-4 alkyl optionally substituted with phenyl, indolyl, methylsulfide, hydroxy, thiol, hydroxyphenyl, aminocarbonyl, hydroxycarbonyl, amine, imidazoyl or guanidino; R 23 represents Ar 3 , Ar 4 -C 1-4 alkyl, C 2-6 alkenyl optionally substituted with Het 12 or R 23 represents C 1-4 alkyl substituted with one or where possible two or more substituents selected from C 1-4 alkyloxy, hydroxy, halo, Het 2 , NR 7 R 8 , NR 9 R 10 -carbonyl or Het 3 -carbonyl;
Het 1 represents a heterocycle selected from piperidinyl, morpholinyl, piperazinyl, furanyl, pyrazolyl, dioxolanyl, thiazolyl, oxazolyl, imidazolyl, isoxazolyl, oxadiazolyl, pyridinyl or pyrrolidinyl wherein said Het 1 is optionally substituted with amino, C 1-4 alkyl, hydroxy-C 1-4 alkyl-, phenyl, phenyl-C 1-4 alkyl-, C 1-4 alkyl-oxy-C 1-4 -alkyl- mono- or di(C 1-4 alkyl)amino- or amino-carbonyl-;
Het 2 represents a heterocycle selected from morpholinyl, piperazinyl, piperidinyl, pyrrolidinyl, thiomorpholinyl or dithianyl wherein said Het 2 is optionally substituted with one or where possible two or more substituents selected from hydroxy, halo, amino, C 1-4 alkyl-, hydroxy-C 1-4 alkyl-, C 1-4 alkyl-oxy-C 1-4 alkyl-, hydroxy-C 1-4 alkyl-oxy-C 1-4 alkyl-, mono- or di(C 1-4 alkyl)amino-, mono- or di(C 1-4 alkyl)amino-C 1-4 alkyl-aminoC 1-4 alkyl-, mono- or di(C 1-4 alkyl)amino-sulfonyl-, aminosulfonyl-;
Het 3 , Het 4 and Het 8 each independently represent a heterocycle selected from morpholinyl, piperazinyl, piperidinyl, furanyl, pyrazolyl, dioxolanyl, thiazolyl, oxazolyl, imidazolyl, isoxazolyl, oxadiazolyl, pyridinyl or pyrrolidinyl wherein said Het 3 , Het 4 or Het 8 is optionally substituted with one or where possible two or more substituents selected from hydroxy-, amino-, C 1-4 alkyl-,
C 3-6 cycloalkyl-C 1-4 alkyl-, aminosulfonyl-, mono- or di (C 1-4 alkyl) aminosulfonyl or amino-C i-4 alkyl-;

Het 9 and Het 10 each independently represent a heterocycle selected from furanyl, piperidinyl, morpholinyl, piperazinyl, pyrazolyl, dioxolanyl, thiazolyl, oxazolyl, imidazolyl, isoxazolyl, oxadiazolyl, pyridinyl or pyrrolidinyl wherein said Het 9 or Het 10 is optionally substituted C 1-4 alkyl, C 3-6 cycloalkyl-C 1-4 alkyl- or amino-C 1-4 alkyl-;
Het 11 represents a heterocycle selected from indolyl or

Het 12 represents a heterocycle selected from morpholinyl, piperazinyl, piperidinyl, pyrrolidinyl, thiomorpholinyl or dithianyl wherein said Het 12 is optionally substituted with one or where possible two or more substituents selected from hydroxy, halo, amino,
C 1-4 alkyl-, hydroxy-C 1-4 alkyl-, C 1-4 alkyl-oxy-C 1-4 alkyl-, hydroxy-C 1-4 alkyl-oxy-C 1-4 alkyl-, mono- or di(C 1-4 alkyl)amino- or mono- or
di(C 1-4 alkyl)amino-C 1-4 alkyl-;

Het 16 represents a heterocycle selected from morpholinyl, pyrrolidinyl, piperazinyl, 1,3,2-dioxaborolane or piperidinyl wherein said heterocycle is optionally substituted with one or more C 1-4 alkyl groups;
Het 17 represents a heterocycle selected from pyrrolidinyl or piperidinyl optionally substituted with one or where possible two or more substituents selected from C 1-4 alkyl, C 3-6 cycloalkyl, hydroxy-C 1-4 alkyl-, C 1-4 alkyloxyC 1-4 alkyl or polyhydroxy-C 1-4 alkyl-;
Het 18 and Het 19 each independently represent a heterocycle selected from morpholinyl, pyrrolidinyl, piperazinyl or piperidinyl optionally substituted with one or where possible two or more substituents selected from C 1-4 alkyl, C 3-6 cycloalkyl, hydroxy-C 1-4 alkyl-, C 1-4 alkyloxyC 1-4 alkyl or polyhydroxy-C 1-4 alkyl-; and
Ar 1 , Ar 2 , Ar 3 , Ar 4 and Ar 5 each independently represent phenyl optionally substituted with cyano,
C 1-4 alkylsulfonyl-, C 1-4 alkylsulfonylamino-, aminosulfonylamino-, hydroxy-C 1-4 alkyl, aminosulfonyl-, hydroxy-, C 1-4 alkyloxy- or C 1-4 alkyl.

Assignees

• Janssen Pharmaceutica Nv
• Janssen Pharmaceutica Nv

Inventors

• Freyne Eddy Jean Edgard
• Perera Timothy Pietro Suren
• Buijnsters Peter Jacobus Johannes Antonius
• Willems Marc
• Diels Gaston Stanislas Marcella
• Embrechts Werner Constant Johan
• Ten Holte Peter
• Rombouts Frederik Jan Rita
• Schultz-Fademrecht Carsten

Classifications

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• C07D498/06 Primary

  Peri-condensed systems · CPC title